830 | A PHASE 1 STUDY EVALUATING SAFETY, PHARMACOKINETICS, AND EFFICACY OF ABBV‐291, A CD79B‐TARGETING ADC IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA

Documenti analoghi

• 667 | REAL‐WORLD SAFETY AND EFFICACY OF EPCORITAMAB FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS
  di: A. M. Bock, et al.
  Pubblicazione: (2025)
• 95 | A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF XNW5004, A SELECTIVE EZH2 INHIBITOR, IN SUBJECTS WITH RELAPSED/ REFRACTORY NON‐HODGKIN LYMPHOMA
  di: W. Zheng, et al.
  Pubblicazione: (2025)
• 570 | EFFICACY AND SAFETY OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
  di: D. Maruyama, et al.
  Pubblicazione: (2025)
• 323 | A PROSPECTIVE ANALYSIS OF THE SAFETY AND EFFICACY OF PROPHYLACTIC DEXAMETHASONE FOR GLOFITAMAB ADMINISTRATION IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
  di: J. E. Haydu, et al.
  Pubblicazione: (2025)
• 438 | ORELABRUTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM A GLOBAL PHASE 1/2 STUDY
  di: Y. Wang, et al.
  Pubblicazione: (2025)